Latest Hematopoietic stem cell transplantation Stories

Brett Smith for redOrbit.com - Your Universe Online Job training can allow workers to take on new responsibilities and a team of oncologists from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York found that the same thing applies to the body’s immune system. By essentially taking T cells, a type of white blood cell, back to school – the oncologists were able to successfully eradicate a certain type of acute leukemia. Similar previous research has shown promise in young...

Leading bone marrow donor center unveils aggressive nationwide initiative under new name to boost donor numbers NEW YORK, March 21, 2013 /PRNewswire/ -- Every year, more than 12,000 patients in the U.S. are diagnosed with blood cancers for which a bone marrow transplant may be their only hope for a cure. 70% of patients in need rely on a perfect stranger for a bone marrow donation. DKMS Americas, part of the world's largest bone marrow donor center announced today that they are...

WASHINGTON, March 14, 2013 /PRNewswire-USNewswire/ -- Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). HS is an inherited metabolic disease characterized by the lack of a...

EYSINS, Switzerland, March 11, 2013 /PRNewswire/ -- Biosafe is proud to announce that it is celebrating a landmark, with the manufacture of the one millionth proprietary SEPAX separation chamber for cord blood processing kits. This milestone confirms that SEPAX has become the industry standard in cord blood banking, as it has been used in almost half of worldwide processing procedures for cord blood inventory. (Logo: http://photos.prnewswire.com/prnh/20121119/574143 )...

RESEARCH TRIANGLE PARK, N.C., March 8, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined. Morgan...

Plano, Texas locals rally to find a donor for six-year-old Aidan Peterson with an on-site bone marrow donor drive, music, entertainment and more at Henry's Tavern Event March 2, 2013 PLANO, Texas, Feb. 28, 2013 /PRNewswire/ -- Henry's Tavern is hosting a family-friendly bone marrow donor drive Saturday, Mar. 2 from 1-4 p.m. for Aidan Peterson. This Henry's Tavern Event will help Aidan and countless others who desperately need a lifesaving bone marrow transplant - are you the one to...

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Ernest Mario, Ph.D., as Chairman of its Board of Directors. "Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms. His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through Phase...

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the BMT Tandem Meetings supporting the broad spectrum antiviral activity and emerging safety profile of CMX001. CMX001 is an oral nucleotide lipid-conjugate anticipated to start a Phase 3 study later this year. "These findings demonstrate CMX001's potential to...

CHICAGO and WHITE PLAINS, N.Y., Feb. 14, 2013 /PRNewswire/ -- In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant, seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF). The challenge resulted in many high quality applications, therefore, the two organizations are continuing with a second round of applications. Applicants for this concept grant...

In the news release, The Expected Approval of Velcade Will Be a Significant Driver of Growth in the Graft Versus Host Disease Drug Market, issued 07-Feb-2013 by Decision Resources over PR Newswire, we are advised by the company that there have been several revisions to the release. The complete, corrected release follows: Physicians' Adoption of Velcade for the Treatment of Chronic Graft Versus Host Disease Will Drive Growth In This Market Through 2021 Uptake of Velcade in the First-Line...